Clinical Trial

ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a phase I/II, single-arm, open-lable study of autologous stem cell transplantation in combination with C-CAR088, an autologous BCMA CAR-T cell product, for patients with ulta high-risk multiple myeloma, defined as failed or unsatisfied responses to front line VRD-based treatment with or without the presence of multiple high-risk cytogenetic features.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2025-10-30 -> 2026-09-30 2026-08-08
minor Completion pushed: 2026-04-30 -> 2026-10-30 2026-08-08
Trial Details
NCT Number NCT05632380
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Collaborators: Shanghai AbelZeta Ltd.
Conditions Multiple Myeloma
Enrollment 20 participants
Start Date 2022-07-14
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-07